Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THR-149 vs Aflibercept in DME (KALAHARI)
NCT04527107Phase 2Completed
- Sponsor
- Oxurion
- Start
- Jul 2020
- Primary completion
- Sep 2023
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 8
01
Overview
A Phase 2 trial of THR-149 in diabetic macular edema (DME), sponsored by Oxurion. Started Jul 2020; status: completed.
02
Drugs
THR-149
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04527107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04527107.